ALPMF (Astellas Pharma) Other Gross PPE : $2,163 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Other Gross PPE?

Astellas Pharma's Other Gross PPE for the quarter that ended in Dec. 2024 was $2,163 Mil.

Astellas Pharma's quarterly Other Gross PPE increased from Jun. 2024 ($1,962 Mil) to Sep. 2024 ($2,206 Mil) but then declined from Sep. 2024 ($2,206 Mil) to Dec. 2024 ($2,163 Mil).

Astellas Pharma's annual Other Gross PPE declined from Mar. 2022 ($2,269 Mil) to Mar. 2023 ($2,143 Mil) and declined from Mar. 2023 ($2,143 Mil) to Mar. 2024 ($1,961 Mil).

Astellas Pharma Other Gross PPE Historical Data

The historical data trend for Astellas Pharma's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Other Gross PPE Chart

Astellas Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Other Gross PPE

Get a 7-Day Free Trial

2,494.72

2,434.45

2,268.93

2,143.12

1,960.65

Astellas Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															2,007.40	1,960.65	1,961.78	2,205.92	2,163.15

Astellas Pharma Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.